🇺🇸 FDA
Patent

US 9228007

Recombinant human progenitor cells, engineered human thymocytes, and engineered human T cells

granted A61KA61K40/10A61K40/11

Quick answer

US patent 9228007 (Recombinant human progenitor cells, engineered human thymocytes, and engineered human T cells) held by The Regents of the University of California expires Mon Dec 31 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Jan 05 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 31 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61K, A61K40/10, A61K40/11, A61K40/32, A61K40/46